
News|Articles|July 1, 2004
TNF inhibitor use associated with granulomatous infectious disease; infliximab poses greatest risk
Tumor necrosis factor (TNF) antagonists increase the risk of granulomatous infectious disease, including tuberculosis, according to a study-the largest of its kind to date-published in the journal Clinical Infectious Diseases. The risk of infection was 3.25-fold greater among patients who received infliximab (Remicade, Centocor) than among those who received etanercept (Enbrel, Wyeth/Amgen), the study found.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Biosimilars in 2025: A year of firsts
2
Music and painting dual art therapy improves cognitive and social functions of hospitalized schizophrenia patients, study suggests
3
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
4
Japanese study finds vitiligo has a strong impact on daily life and mental health
5






















































